A NOVEL DELAYED-RELEASE RISEDRONATE 35 MG ONCE-A-WEEK FORMULATION TAKEN WITH OR WITHOUT BREAKFAST: 2-YEAR BMD DATA

被引：0

作者：

Benhamou, Claude-Laurent ^{[1
]}

Zanchetta, Jose ^{[3
]}

Kaufman, Jean-Marc ^{[2
]}

Brown, Jacques ^{[4
]}

Maasalu, Katre ^{[5
]}

Lakatos, Peter ^{[6
]}

Badurski, Janusz ^{[7
]}

Wenderoth, Dietrich ^{[8
]}

McClung, Michael ^{[9
]}

机构：

[1] CHR Orleans, INSERM, Unit U658, Orleans, France

[2] Univ Ghent, Dept Endocrinol, B-9000 Ghent, Belgium

[3] Inst Invest Metab, Buenos Aires, DF, Argentina

[4] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada

[5] Tartu Univ Hosp, Dept Traumatol & Orthopaed, Tartu, Estonia

[6] Semmelweis Univ, Dept Med 1, Budapest, Hungary

[7] Ctr Osteoporosis & Osteoarticular Dis, Dept Med & Rheumatol, Bialystok, Poland

[8] Warner Chilcott, Darmstadt, Germany

[9] Oregon Osteoporosis Ctr, Portland, OR USA

来源：

OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：337 / 338

页数：2

共 8 条

[1] EFFECT OF A DELAYED-RELEASE RISEDRONATE 35 MG ONCE-A-WEEK FORMULATION TAKEN WITH OR WITHOUT BREAKFAST ON BMD
McClung, M. R.
Zanchetta, J. R.
Benhamou, C. L.
Balske, A.
Sarley, J.
Recker, R. R.
OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 25 - 25
[2] Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
M. R. McClung
P. D. Miller
J. P. Brown
J. Zanchetta
M. A. Bolognese
C. L. Benhamou
A. Balske
D. E. Burgio
J. Sarley
L. K. McCullough
R. R. Recker
Osteoporosis International, 2012, 23 : 267 - 276
[3] Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
McClung, M. R.
Miller, P. D.
Brown, J. P.
Zanchetta, J.
Bolognese, M. A.
Benhamou, C. L.
Balske, A.
Burgio, D. E.
Sarley, J.
McCullough, L. K.
Recker, R. R.
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) : 267 - 276
[4] Two year vertebral fracture risk reduction with risedronate 35 mg once-a-week
Watts, NB
Lindsay, R
Li, Z
Kasibhatla, C
Brown, J
OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S36 - S36
[5] Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
McClung, M. R.
Balske, A.
Burgio, D. E.
Wenderoth, D.
Recker, R. R.
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 301 - 310
[6] Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
M. R. McClung
A. Balske
D. E. Burgio
D. Wenderoth
R. R. Recker
Osteoporosis International, 2013, 24 : 301 - 310
[7] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
M. R. McClung
J. R. Zanchetta
A. Racewicz
C. Roux
C.-L. Benhamou
Z. Man
R. A. Eusebio
J. F. Beary
D. E. Burgio
E. Matzkin
S. Boonen
P. Delmas
Osteoporosis International, 2013, 24 : 293 - 299
[8] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
McClung, M. R.
Zanchetta, J. R.
Racewicz, A.
Roux, C.
Benhamou, C. -L.
Man, Z.
Eusebio, R. A.
Beary, J. F.
Burgio, D. E.
Matzkin, E.
Boonen, S.
Delmas, P.
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299

← 1 →